Xperiome is a technology company.
Xperiome has raised $4.0M across 1 funding round.
Xperiome has raised $4.0M in total across 1 funding round.
Xperiome is a global health technology company focused on accelerating pharmaceutical understanding of rare disease patients by delivering deep insights into their lived experiences. It builds the Xperiome platform, a patient-powered knowledge base that aggregates real-world data from thousands of rare disease patients and caregivers, enabling pharma companies to better understand patient conditions, improve clinical trial recruitment, and develop more effective treatments. The platform serves pharmaceutical researchers, clinicians, and patients by addressing the challenge of scarce, fragmented data in rare diseases, thereby enhancing drug development and patient care. Xperiome has shown strong growth momentum, evolving from its origins as Raremark to become a key player in rare disease healthtech[1][2][3].
Founded originally as Raremark, Xperiome emerged from the need to connect and empower rare disease patients while providing pharma with actionable patient insights. The company was founded by experts in health technology and patient advocacy, with pivotal moments including the launch of the Raremark community and subsequent rebranding to Xperiome to reflect its expanded data-driven platform capabilities. The appointment of healthtech leader Dale Jessop as CTO marked a strategic evolution toward leveraging machine learning and behavioral science to enhance data collection and analysis. Early traction came from building a large, engaged patient community and forming partnerships with clinical technology providers to improve rare disease study recruitment and retention[2][3][4].
Xperiome rides the growing trend of patient-centric, data-driven healthcare innovation, particularly in the rare disease sector where traditional clinical data is sparse. The timing is critical as pharmaceutical companies face increasing pressure to accelerate drug development and demonstrate patient value. Advances in machine learning and decentralized clinical trials amplify Xperiome’s impact by enabling faster, more efficient patient recruitment and richer data collection. By bridging patient communities and pharma, Xperiome influences the broader ecosystem toward more inclusive, real-world evidence-based research and personalized medicine[2][4].
Looking ahead, Xperiome is poised to expand its platform capabilities, deepen pharma partnerships, and scale its patient community globally. Trends such as increased regulatory emphasis on patient-reported outcomes, growth in decentralized trials, and advances in AI-driven data analytics will shape its trajectory. Its influence is likely to grow as a critical enabler of rare disease research, helping to reduce time-to-market for therapies and improve patient outcomes. Xperiome’s evolution from a patient community to a comprehensive healthtech platform exemplifies the future of patient-centered innovation in biopharma.
Xperiome has raised $4.0M in total across 1 funding round.
Xperiome's investors include Albion VC, Ananda Impact Ventures.
Xperiome has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Series A in October 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2018 | $4.0M Series A | Albion VC, Ananda Impact Ventures |